CN108159146A - A kind of Chinese medicine composition and preparation method for reducing blood lipid - Google Patents
A kind of Chinese medicine composition and preparation method for reducing blood lipid Download PDFInfo
- Publication number
- CN108159146A CN108159146A CN201810104820.3A CN201810104820A CN108159146A CN 108159146 A CN108159146 A CN 108159146A CN 201810104820 A CN201810104820 A CN 201810104820A CN 108159146 A CN108159146 A CN 108159146A
- Authority
- CN
- China
- Prior art keywords
- extraction process
- chinese medicine
- group
- extraction
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 56
- 239000000203 mixture Substances 0.000 title abstract description 45
- 210000004369 blood Anatomy 0.000 title abstract description 34
- 239000008280 blood Substances 0.000 title abstract description 34
- 150000002632 lipids Chemical class 0.000 title description 15
- 238000002360 preparation method Methods 0.000 title description 9
- 238000000605 extraction Methods 0.000 claims abstract description 48
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 30
- 229940079593 drug Drugs 0.000 claims abstract description 15
- 239000007787 solid Substances 0.000 claims description 28
- 239000007788 liquid Substances 0.000 claims description 21
- 238000001914 filtration Methods 0.000 claims description 20
- 239000000284 extract Substances 0.000 claims description 17
- 238000000926 separation method Methods 0.000 claims description 17
- 239000000706 filtrate Substances 0.000 claims description 13
- 238000001471 micro-filtration Methods 0.000 claims description 12
- 238000005119 centrifugation Methods 0.000 claims description 11
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims description 9
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims description 9
- 235000009685 Crataegus X maligna Nutrition 0.000 claims description 9
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims description 9
- 235000009486 Crataegus bullatus Nutrition 0.000 claims description 9
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims description 9
- 235000009682 Crataegus limnophila Nutrition 0.000 claims description 9
- 235000004423 Crataegus monogyna Nutrition 0.000 claims description 9
- 235000002313 Crataegus paludosa Nutrition 0.000 claims description 9
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims description 9
- 244000037364 Cinnamomum aromaticum Species 0.000 claims description 8
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims description 8
- 240000002853 Nelumbo nucifera Species 0.000 claims description 8
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims description 8
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims description 8
- 240000001341 Reynoutria japonica Species 0.000 claims description 8
- 235000018167 Reynoutria japonica Nutrition 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 239000012528 membrane Substances 0.000 claims description 7
- 238000004140 cleaning Methods 0.000 claims description 5
- 238000007781 pre-processing Methods 0.000 claims description 2
- 240000000171 Crataegus monogyna Species 0.000 claims 1
- 241000700159 Rattus Species 0.000 abstract description 23
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 20
- 230000000694 effects Effects 0.000 abstract description 19
- 210000002966 serum Anatomy 0.000 abstract description 19
- 235000012000 cholesterol Nutrition 0.000 abstract description 8
- 238000004519 manufacturing process Methods 0.000 abstract description 7
- 230000002829 reductive effect Effects 0.000 abstract description 7
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract description 7
- 108010007622 LDL Lipoproteins Proteins 0.000 abstract description 5
- 102000007330 LDL Lipoproteins Human genes 0.000 abstract description 5
- 201000001320 Atherosclerosis Diseases 0.000 abstract description 4
- 239000010296 Jiang-Zhi-Ning Substances 0.000 abstract description 4
- 239000004480 active ingredient Substances 0.000 abstract description 4
- 230000007613 environmental effect Effects 0.000 abstract description 4
- 238000002474 experimental method Methods 0.000 abstract description 4
- 239000003960 organic solvent Substances 0.000 abstract description 4
- 239000002904 solvent Substances 0.000 abstract description 4
- 230000000144 pharmacologic effect Effects 0.000 abstract description 3
- 230000000052 comparative effect Effects 0.000 description 38
- 238000000034 method Methods 0.000 description 12
- 239000000463 material Substances 0.000 description 10
- OJRHUICOVVSGSY-RXMQYKEDSA-N (2s)-2-chloro-3-methylbutan-1-ol Chemical compound CC(C)[C@H](Cl)CO OJRHUICOVVSGSY-RXMQYKEDSA-N 0.000 description 9
- 239000000341 volatile oil Substances 0.000 description 9
- 241001092040 Crataegus Species 0.000 description 8
- 108010023302 HDL Cholesterol Proteins 0.000 description 7
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 230000002776 aggregation Effects 0.000 description 6
- 238000004220 aggregation Methods 0.000 description 6
- 208000031226 Hyperlipidaemia Diseases 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000007547 defect Effects 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 201000005577 familial hyperlipidemia Diseases 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 108090001030 Lipoproteins Proteins 0.000 description 4
- 102000004895 Lipoproteins Human genes 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000002969 egg yolk Anatomy 0.000 description 4
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 238000010010 raising Methods 0.000 description 4
- 239000003390 Chinese drug Substances 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000005352 clarification Methods 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000005374 membrane filtration Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 108010071619 Apolipoproteins Proteins 0.000 description 2
- 102000007592 Apolipoproteins Human genes 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 229960002662 propylthiouracil Drugs 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010062714 Dysglobulinaemia Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010061998 Hepatic lesion Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 1
- 102100022119 Lipoprotein lipase Human genes 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 108010046644 Polymeric Immunoglobulin Receptors Proteins 0.000 description 1
- 102100035187 Polymeric immunoglobulin receptor Human genes 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical class [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 229960001770 atorvastatin calcium Drugs 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 238000002309 gasification Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002394 glycogenic effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000003516 hyperlipidaemic effect Effects 0.000 description 1
- 208000020346 hyperlipoproteinemia Diseases 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000008604 lipoprotein metabolism Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000015689 metaplastic ossification Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000003617 peroxidasic effect Effects 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000021510 thyroid gland disease Diseases 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to drug fields, more particularly to drug and its extraction process.Water is selected to avoid a large amount of uses of organic solvent, Environmental Safety as solvent in the extraction process.In addition, being extracted using cryogenic high pressure difference, active ingredient is made to extract to the greatest extent, improve production efficiency.Pharmacological experiments show, mouse high cholesterol caused by Chinese medicine composition can be substantially reduced egg-nog made from extraction process provided by the invention, it improves significantly to experimental atherosclerosis rats hemorheology tool, whole blood viscosity can be reduced, cholesterol, triglyceride and the low-density lipoprotein content in serum are reduced, there is apparent effect for reducing blood fat.Effect for reducing fat with Chinese medicine composition of the present invention under dosage is apparent compared with JIANGZHINING KELI.
Description
Technical field
The present invention relates to drug field, more particularly to a kind of Chinese medicine compositions and preparation method for reducing blood lipid.
Background technology
Due to the raising of quality of life, hyperglycemia, hyperlipidemia, hypertension, which are increasingly becoming, threatens the three of human health to kill greatly
Hand, and the trend of rejuvenation is presented, seriously affect people’s lives quality.And most of hyperlipemic patients have simultaneously
Hypertension symptom is easy to cause the generation of apoplexy, angiocardiopathy, if cannot prevent and treat early, consequence is very serious.
Hyperlipemia can be divided into primary and secondary two class.In Patients With Primary Hyperlipoidemia is related with congenital and heredity, is
Due to single-gene defect or polygenes defect, portable, the enzyme activity apolipoprotein caused by abnormal that participation lipoprotein is made to transport and be metabolized,
Or it is caused due to environmental factor (diet, nutrition, drug) and by unknown mechanism.1. inherent cause：Heredity can be by a variety of
Mechanism causes hyperlipidemia, certain possible lists be happened at cellular level it is famous on, want to buy and be mainly shown as cell surface fat egg
The defects of polymeric immunoglobulin receptor defect and intracellular certain enzymes (the defects of such as lipoprotein lipase or shortage), may also occur at lipoprotein or
On the molecule of apolipoprotein, mostly and to be caused due to gene defect.2. dietary factor：Dietary factor effect checks more eternal abdomen
Chamber is complicated, and patients with hyperlipoproteinemia has sizable ratio in being hospitalized be closely related with dietary factor.Secondary high blood
Fat disease is since those caused by other intermediate primary diseases, these diseases include：Diabetes, hepatopathy, thyroid disease, kidney disease
Disease, pancreas, obesity, glycogenic thesaurismosis, gout, Addision's disease, Cushing's syndrome, dysglobulinemia etc..1. diabetes
Have between glycometabolism and fat metabolism in human body with hyperlipoprotememia it is close contact, only clinical research is found, about
40% diabetic secondary can cause hyperlipidemia.2. hepatopathy and hyperlipoprotememia：The confirmation of modern medicine study data,
The many substances of fatigue are processed, produce and decompose, drain in liver including lipid and lipoprotein etc..Once liver is ill
Medical insurance, then lipid and lipoprotein metabolism will also get muddled.3. obesity and hyperlipoprotememia：Clinic study data
Show that obesity most Chang Jifa causes blood triglyceride content to increase, some patientss cholesterolemia content first may also can increase
Height is mainly shown as iv type hyperlipoprotememias too much, is secondly iib type hyperlipoprotememias.Secondary hyperlipemia may be used also
Can with other factors such as the age, gender, season, drink, smoke, diet, physical exertion, stress, have emotional activity
It closes.
Clinically the drug of common reducing blood lipid has Statins, is inhibitor of cholesterol biosynthetic enzyme, is clinical at present
Most widely used one kind lipid-regulation medicine and the at present key agents for the treatment of hypercholesterolemia, there are stomach and intestine for such drug
Reaction, headache, musclar toxicity is likely to occur when being shared with other fat-reducing medicaments；Fibrates are mainly used for hypertriglyceridemia
Or triglycerides raising based on mixed type hyperlipidemia mass formed by blood stasis, the common adverse reaction of the medicine be gastrointestinal reaction, nausea, diarrhea,
Severe patient can lead to hepatic lesion.Therefore, although these medicines have the effect of certain, but side effect is larger, for fitness compared with
For weak crowd, be not suitable for using.
For Western medicine, Chinese medicine have safety, few side effects, it is not damaged to gastrointestinal tract, liver kidney is stimulated it is small excellent
Point, has been to be concerned by more and more people.
JIANGZHINING KELI is made of hawthorn, prepared fleece flower root, cassia seed, four taste Chinese medicine of lotus leaf.Its major function is reducing blood lipid,
Soften blood vessel.For enhancing coronary flow cycle.Arrhythmia and hyperlipemia.Its prescription, which records, at present issues mark in portion
Quasi- WS3-B-2549-97.
In current preparation process, hawthorn is more containing sugar after water decocts, and is not easy to filter after concentration, is not easy drying, causes
The moisture absorption repeatedly influences production efficiency.And largely using organic solvent in extraction process, a large amount of waste liquor contamination environment are unfavorable for work
Industry metaplasia is produced.
Invention content
In view of this, the present invention provides a kind of Chinese medicine compositions and preparation method for reducing blood lipid.In extraction process
Water is selected to avoid a large amount of uses of organic solvent, Environmental Safety as solvent.In addition, extracting using cryogenic high pressure difference, make to have
Effect ingredient extracts to the greatest extent, improves production efficiency.Pharmacological experiments show extraction process system provided by the invention
Mouse high cholesterol caused by the Chinese medicine composition obtained can be substantially reduced egg-nog, to experimental atherosclerosis rats blood stream
Become learning aid to improve significantly, whole blood viscosity can be reduced, reduce cholesterol, triglyceride and low density lipoprotein in serum
Protein content has apparent effect for reducing blood fat.Effect for reducing fat with Chinese medicine composition of the present invention under dosage is compared with JIANGZHINING KELI
Significantly.
In order to achieve the above-mentioned object of the invention, the present invention provides following technical scheme：
A kind of extraction process of drug of the present invention, includes the following steps：
Bulk pharmaceutical chemicals include 500~600 parts by weight of hawthorn, 10~35 parts by weight cassia seed of prepared fleece flower root, 10~35 parts by weight,
50~100 parts by weight of lotus leaf；
Step 1：Bulk pharmaceutical chemicals is taken to be mixed after pre-processing with water；
Step 2：In 20~30Mpa, 30~60min of extraction for the first time, 30 are extracted then at 40~50Mpa second~
60min；
Step 3：The extract that step 2 obtains is taken to collect filtrate through separation of solid and liquid.
In some specific embodiments of the present invention, the mass ratio of the bulk pharmaceutical chemicals and water is 1：(10~20).
The present invention some specific embodiments in, the bulk pharmaceutical chemicals mixed with water the time be 50~70min.
In some specific embodiments of the present invention, the temperature of the first time extraction is 0~10 DEG C.
In some specific embodiments of the present invention, the temperature of second of extraction is 0~10 DEG C.
In some specific embodiments of the present invention, separation of solid and liquid described in step 3 is centrifugation or filtering；The centrifugation
Rotating speed for 8000~12000rpm, the time of the centrifugation is 10~30min.
In some specific embodiments of the present invention, the step of filtrate is taken to repeat step 2, step 3, institute are further included
The number for stating repetition is at least 1 time.
The present invention some specific embodiments in, repeat step 2, step 3 the step of after further include merging filtrate,
The step of filtering；It is described to be filtered into micro-filtration；
The aperture for the film that the micro-filtration uses is 0.45~1.0 μm.
In some specific embodiments of the present invention, the micro-filtration is specially that the filtrate after merging is taken to cross microfiltration membranes, is added
Water makes to be no less than 2 times of the volume of the filtrate after the merging through liquid measure, and the content for filtering into dope solid content is no less than
20% (w/w)；Microfiltration membranes are rinsed with water, cleaning solution is collected and is mixed with the dope.
In some specific embodiments of the present invention, the time of the filtering is no more than 6h, and the flow of the filtering drops
Low amplitude is no less than 50%.
The present invention some specific embodiments in, in the filtering content of solid content be 10~20% (w/w), 50
The relative density measured at~80 DEG C is 1.05~1.20.
The present invention also provides drugs made from the extraction process.
Water is selected to avoid a large amount of uses of organic solvent, environmental protection peace as solvent in extraction process provided by the invention
Entirely.In addition, being extracted using cryogenic high pressure difference, active ingredient is made to extract to the greatest extent, improve production efficiency.Pharmacological research
The result shows that the high courage of mouse caused by Chinese medicine composition can be substantially reduced egg-nog made from extraction process provided by the invention
Sterol improves significantly to experimental atherosclerosis rats hemorheology tool, can reduce whole blood viscosity, reduces blood
Cholesterol, triglyceride and low-density lipoprotein content in clear have apparent effect for reducing blood fat.With in the present invention under dosage
The effect for reducing fat of drug composition is apparent compared with JIANGZHINING KELI.
Specific embodiment
The invention discloses a kind of Chinese medicine composition and preparation method for reducing blood lipid, those skilled in the art can borrow
Reflect present disclosure, is suitably modified technological parameter realization.In particular, it should be pointed out that all similar substitutions and modifications are to this field
It is it will be apparent that they are considered as being included in the present invention for technical staff.The method of the present invention and application have passed through
Preferred embodiment is described, related personnel significantly can not depart from the content of present invention, in spirit and scope to described herein
Methods and applications be modified or suitably change with combining, to realize and using the technology of the present invention.
1. experiment material
1.1 test sample：1~3 Chinese medicine composition of the embodiment of the present invention, is carried by Jilin Revision Medicine New Medicine Development Co., Ltd
For.
Control group 1：Chinese medicine composition made from comparative example 1；
Control group 2：Chinese medicine composition made from comparative example 2；
1.2 reagent
Yolk emulsion：75% yolk normal saline suspension；High lipoprotein emulsion：20% cholesterol, 1% propylthiouracil (PTU),
40% lard, 20% pig gall acid sodium solution (a concentration of l0%), 1% tween, 2% propylene glycol add distilled water to 100mL compositions；
Atorvastatin calcium：Pfizer inc, specification：20mg/ pieces, lot number：M97466；
Serum total cholesterol (TC)；Triglyceride (TG)；High-density lipoprotein cholesterol (HDL-cho) and low-density lipoprotein
White cholesterol (LDL-cho) assay kit, is purchased from Nanjing and builds up Bioengineering Research Institute.
2. experimental animal
Wistar rats, male, 240-260g；ICR mouse, half male and half female, 18-22g, quality certification number：SCXK (Ji)
2014-0003.Source：This experimental animal technology Co., Ltd of Changchun hundred million, experimental animal production licence number：SCXK
(Ji) 2014-0003.Licence issuing authority：Jilin Department of Science and Technology of Shanxi Province, the certification of fitness number：37009200005847.
3. instrument
Electronic balance, Minqiao Precision Scientific Instruments Co., Ltd., Shanghai, JA1103N；LBY-N6 automatic blood rheologic meters,
Pulisheng Instruments Co., Ltd., Beijing；Microplate reader (SMP500-18272-LSIO, Manufactured in China
Designed in California USA)；LBY-NJ4 platelet aggregation instruments, thyrite health letter.
Raw materials used and reagent can be bought by market in drug provided by the invention and its extraction process.
With reference to embodiment, the present invention is further explained：
Embodiment 1
Formula：Hawthorn 55kg prepared fleece flower root 2.5kg cassia seed 1kg lotus leaves 5kg
(1) it is sieved after taking the pulverizing medicinal materials of formula ratio by No.1 (10 mesh)~No. tetra- (65 mesh)；
(2) above-mentioned weight medicinal powder is taken to mix, 10 times of amount water is added to be stirred 60min, make fully to soak；
(3) it extracts for the first time：It sets low in warm High Pressure Difference extractor, in 5 DEG C of cycle extractions 2 times, first time 30Mpa, extraction
60min, second of 40Mpa extract 45min；
(4) separation of solid and liquid：By the slurry of extraction through centrifugation (rotating speed 8000rpm, the time of centrifugation is 20min) or filtering
Make separation of solid and liquid, the solid content that control is transferred in extracting solution is no more than the 20% of medicinal material total amount, the extracting solution meter of separation
It measures spare.
(5) it extracts for second：The solid dregs of a decoction of separation of solid and liquid are repeated into step 3~4, extraction fluid metering and first time
The extracting solution of extraction is combined into step 6；
(6) micro-filtration：By the extracting solution of merging through 0.45 μm of inorganic membrane filtration to clarification；6.1 filtering to close to microstrainer most
During partial circulating, add extraction that filter liquor is diluted with water, make to be no less than 2 times of extracting solution through liquid measure, continue filtering to dope and consolidate
More than 20% shape object content.Filtered solution and dope are collected respectively.
6.2 are recycled 15 minutes with the water of microstrainer minimal circulation amounts and rinse inorganic membrane filter, by cleaning solution with 6.1 it is dense
Liquid merges.
The filtration time of 6.3 every microstrainers is no more than 6 hours or flow drop is more than 50%.
(7) micro-filtrate is concentrated into solid content about 15%, relative density is the Chinese medical concrete of 1.05 (70 DEG C).
(8) above-mentioned medicinal extract adds proper auxiliary materials to be spray-dried, and obtains Chinese medicine composition of the present invention.
A kind of Chinese medicine composition for reducing blood lipid prepared by the present invention can use existing Chinese drug preparation technique and technique
Any solid dosage forms is made in method, including capsule, tablet, powder or pill etc..Piece agent or particle are prepared in the present embodiment
Agent, but dosage form is not limited.
Embodiment 2
Formula：Hawthorn 50kg prepared fleece flower root 3.5kg cassia seed 3.5kg lotus leaves 10kg.
(1) it is sieved after taking the pulverizing medicinal materials of formula ratio by No.1 (10 mesh)~No. tetra- (65 mesh)；
(2) above-mentioned weight medicinal powder is taken to mix, 20 times of amount water is added to be stirred 70min, make fully to soak；
(3) it extracts for the first time：It sets low in warm High Pressure Difference extractor, in 10 DEG C of cycle extractions 2 times, first time 20Mpa, extraction
40min, second of 50Mpa extract 30min；
(4) separation of solid and liquid：By the slurry of extraction through centrifugation (rotating speed 10000rpm, the time of centrifugation is 15min) or mistake
Filter makes separation of solid and liquid, and the solid content that control is transferred in extracting solution is no more than the 20% of medicinal material total amount, the extracting solution of separation
It measures spare.
(5) it extracts for second：The solid dregs of a decoction of separation of solid and liquid are repeated into step 3~4, extraction fluid metering and first time
The extracting solution of extraction is combined into step 6；
(6) micro-filtration：By the extracting solution of merging through 1.0 μm of inorganic membrane filtrations to clarification；
When 6.1 filterings are to close to microstrainer minimal circulation, add extraction that filter liquor is diluted with water, make to be no less than through liquid measure
2 times of extracting solution continue filtering to more than 20% dope solid content.Filtered solution and dope are collected respectively.
6.2 are recycled 15 minutes with the water of microstrainer minimal circulation amounts and rinse inorganic membrane filter, by cleaning solution with 6.1 it is dense
Liquid merges.
The filtration time of 6.3 every microstrainers is no more than 6 hours or flow drop is more than 50%.
(7) micro-filtrate is concentrated into solid content about 20%, relative density is the Chinese medical concrete of 1.20 (50 DEG C).
(8) above-mentioned medicinal extract adds proper auxiliary materials to be spray-dried, and obtains Chinese medicine composition of the present invention.
A kind of Chinese medicine composition for reducing blood lipid prepared by the present invention can use existing Chinese drug preparation technique and technique
Any solid dosage forms is made in method, including capsule, tablet, powder or pill etc..Piece agent or particle are prepared in the present embodiment
Agent, but dosage form is not limited.
Embodiment 3
Formula：Hawthorn 60kg, prepared fleece flower root 1kg, cassia seed 2.5kg, lotus leaf 8kg.
(1) it is sieved after taking the pulverizing medicinal materials of formula ratio by No.1 (10 mesh)~No. tetra- (65 mesh)；
(2) above-mentioned weight medicinal powder is taken to mix, 15 times of amount water is added to be stirred 50min, make fully to soak；
(3) it extracts for the first time：It sets low in warm High Pressure Difference extractor, in 0 DEG C of cycle extraction 2 times, first time 25Mpa, extraction
30min, second of 45Mpa extract 60min；
(4) separation of solid and liquid：By the slurry of extraction through centrifugation (rotating speed 12000rpm, the time of centrifugation is 10min) or mistake
Filter makes separation of solid and liquid, and the solid content that control is transferred in extracting solution is no more than the 20% of medicinal material total amount, the extracting solution of separation
It measures spare.
(5) it extracts for second：The solid dregs of a decoction of separation of solid and liquid are repeated into step 3~4, extraction fluid metering and first time
The extracting solution of extraction is combined into step 6；
(6) micro-filtration：By the extracting solution of merging through 0.8 μm of inorganic membrane filtration to clarification；
When 6.1 filterings are to close to microstrainer minimal circulation, add extraction that filter liquor is diluted with water, make to be no less than through liquid measure
2 times of extracting solution continue filtering to more than 20% dope solid content.Filtered solution and dope are collected respectively.
6.2 are recycled 15 minutes with the water of microstrainer minimal circulation amounts and rinse inorganic membrane filter, by cleaning solution with 6.1 it is dense
Liquid merges.
The filtration time of 6.3 every microstrainers is no more than 6 hours or flow drop is more than 50%.
(7) micro-filtrate is concentrated into solid content about 10%, relative density is the Chinese medical concrete of 1.1 (80 DEG C).
(8) above-mentioned medicinal extract adds proper auxiliary materials to be spray-dried, and obtains Chinese medicine composition of the present invention.
A kind of Chinese medicine composition for reducing blood lipid prepared by the present invention can use existing Chinese drug preparation technique and technique
Any solid dosage forms is made in method, including capsule, tablet, powder or pill etc..Piece agent or particle are prepared in the present embodiment
Agent, but dosage form is not limited.
Comparative example 1
Formula：Hawthorn (stoning) 500g；Prepared fleece flower root 25g；Cassia seed 25g；Lotus leaf 75g.
(1) raw material is placed：The raw material of formula ratio is crushed, it is 180 μm to make grain size；
(2) it vacuumizes：Under the conditions of -10 DEG C of reaction system temperature, make to be formed in High Pressure Difference continuous low-temperature extractor true
Sky, vacuum degree are maintained at -100pa, add in water or 70% (v/v) ethanol water, keep 5min, wherein, the raw material and water
Or 5% (v/v) ethanol water weight ratio be 1:6；
(3) subtract vacuum：Purification of compressed air is passed through, the pressure in High Pressure Difference continuous low-temperature extractor is made to rise to 0Mpa,
Keep 1min；
(4) it pressurizes：Continue to be passed through compressed air, the pressure in High Pressure Difference continuous low-temperature extractor is made to reach 8Mpa, protect
Hold 20min；
(5) it depressurizes：Stop pressurization, vacuumize, the pressure in High Pressure Difference continuous low-temperature extractor is made to be down to 0Mpa；
(6) cycle extraction：Step (2)-(5) are recycled, are recycled 10 times.
Tablet or granule is made in above-mentioned composition.
Comparative example 2
Formula：Hawthorn 500g；Prepared fleece flower root 25g；Cassia seed 25g；Lotus leaf 60g.
(1) raw material is placed：The raw material of formula ratio is crushed, it is 850 μm to make grain size；
(2) it vacuumizes：Under the conditions of 0 DEG C of reaction system temperature, make to form vacuum in High Pressure Difference continuous low-temperature extractor,
Vacuum degree is maintained at 20pa, adds in water or 5% (v/v) ethanol water, keeps 30min, wherein, the raw material and water or 70%
(v/v) weight ratio of ethanol water is 1:20；
(3) subtract vacuum：Purification of compressed air is passed through, the pressure in High Pressure Difference continuous low-temperature extractor is made to rise to 0Mpa,
Keep 10min；
(4) it pressurizes：Continue to be passed through compressed air, the pressure in High Pressure Difference continuous low-temperature extractor is made to reach 12Mpa, protect
Hold 1min；
(5) it depressurizes：Stop pressurization, vacuumize, the pressure in High Pressure Difference continuous low-temperature extractor is made to be down to 0Mpa；
(6) cycle extraction：Step (2)-(5) are recycled, are recycled 10 times.
Tablet or granule is made in above-mentioned composition.
Influence of the embodiment 4 to hyperlipidemic mice caused by egg-nog
Healthy male ICR kinds mouse 80 is selected, 8 groups is randomly divided by weight, is blank control group, model comparison respectively
Group, atorvastatin calcium group (3mgkg-1), the basic, normal, high dosage group of Chinese medicine composition group made from the embodiment of the present invention 1~3
(2、4、8g·kg-1), 1 group of (4gkg of comparative example-1), 2 groups of (4gkg of comparative example-1).Except blank group daily gavage such as gives at the appearances
Measure distilled water, remaining each group morning gavage gives yolk emulsion 0.5ml/ only, afternoon gastric infusion, administered volume 10ml
kg-1, continuous 11d.Mouse is deprived of food but not water 12h before last dose, and 1h mouse pluck eyeball blood is taken (to test after the last administration
11d), 3000rmin-110min is centrifuged, detaches serum, serum triglyceride (TC), total courage are measured according to kit specification
Sterol (TG) content.
Experimental result：
Model group mice serum TG, TC content significantly increases, and relatively has pole significant difference (p with blank control group<
0.001), atorvastatin calcium group, the basic, normal, high dosage group of Chinese medicine composition group and comparison made from the embodiment of the present invention 1~3
Example 1,2 each groups can obviously reduce hyperlipemia in mice serum TG, TC contents, with significant difference (p compared with model group<
0.05, p<0.01, p<0.001), while the middle and high dosage group of Chinese medicine composition group made from the embodiment of the present invention 1~3 is with comparing
When 1,2 group of example is respectively compared, find that TG, TC content raising effect is inhibited to be substantially better than 1,2 group of comparative example, compare has significantly therewith
Difference (p<0.05, p<0.01) it is, suitable with atorvastatin calcium group effect, it the results are shown in Table 1.
Table 1 to hyperlipemia model mice serum TC, TG caused by egg-nog influence (N=10)
Compared with blank control group△△△p<0.001；The * p compared with model control group<0.05, * * p<0.01,
***p<0.001；Compared with comparative example 1★p<0.05,★★p<0.01；Compared with comparative example 2#p<0.05,##p<
0.01。
Influence of the embodiment 5 to experimental atherosclerosis rats
Model foundation：
By 90 rats in addition to 10 blank control group normal diets, remaining rat gives high lipid food nursing, feeds 8 weeks
Extraction 5 cuts tail and takes whether TG content detection models in blood survey serum succeed afterwards.High lipid food formula：78.8% basal feed,
10% lard, 10% yolk powder, 1% cholesterol, 0.2% cholate.This experimental animal technology Co., Ltd of Changchun hundred million, it is low
Temperature preserves.
Grouping and administration：
By 70 7 groups of modeling successful rats point：That is model control group, atorvastatin calcium group (1mgkg-1), this hair
The basic, normal, high dosage group of Chinese medicine composition group made from bright Examples 1 to 3 (1.5,3,6gkg-1), 1 group of (3gkg of comparative example-1), 2 groups of (3gkg of comparative example-1).Remaining each group continues feeding high fat diet in addition to blank control group normal diet is fed,
Blank control group and the isometric distilled water of model control group gavage, remaining each group gastric infusion, 10mlkg-1, it is administered 4 weeks.
Index：
It is deprived of food but not water 12h after the last administration, rat anaesthetizes (45mgkg with yellow Jackets-1), abdominal aorta blood sampling,
Be put into containing heparin sodium, sodium citrate anticoagulant vacuum blood collection tube in, believe blood with Beijing Puli's green blood viscosity apparatus and thyrite health
Platelet aggregation instrument measures whole blood contrast viscosity and platelet aggregation rate.A pipe blood, 3500rmin are acquired again-1Centrifuge 15min separation
Serum measures T-CHOL (TG), triglyceride (TC), high-density lipoprotein (HDL-C) and low-density lipoprotein in serum
(LDL-C) it is horizontal, superoxides gasification enzyme (SOD) vigor is measured, measures malonaldehyde (MDA) content, kit is pressed in concrete operations
Specification carries out.
Experimental result：
Influence to hemorheology of rat：
Whole blood viscosity under model control group rat blood difference shear rate is significantly raised, relatively has with blank control group
Significant difference (p<0.05, p<0.01, p<0.001), atorvastatin calcium group, Chinese traditional medicine composition made from the embodiment of the present invention 1~3
1,2 group of whole blood viscosity and model control group ratio that can significantly inhibit under each shear rate of the basic, normal, high dosage group of object group and comparative example
More significant difference (p<0.05, p<0.01, p<0.001；).Chinese medicine composition group made from the embodiment of the present invention 1~3 simultaneously
Middle and high dosage group is significantly better than that the inhibiting effect of each point whole blood viscosity 1,2 group of comparative example, there is apparent advantage function (p<
0.05, p<0.01) 2, be the results are shown in Table.
Table 2 to hemorheology of rat influence (N=10)
Compared with blank control group△△p<0.01,△△△p<0.001；The * p compared with model control group<0.05, * * p<
0.01, * * * p<0.001；Compared with comparative example 1★p<0.05,★★p<0.01；Compared with comparative example 2#p<0.05,##p<0.01。
Influence to Rat Erythrocytes aggregation rate and platelet aggregation rate：
Model control group rat blood erythrocyte aggregation rate and maximum platelet aggregation rate also significantly increase, with blank control
Group compares that there were significant differences (p<0.05, p<0.01, p<0.001), atorvastatin calcium group, made from the embodiment of the present invention 1~3
1,2 group of the basic, normal, high dosage group of Chinese medicine composition group and comparative example can significantly inhibit erythrocyte aggregation rate and the big aggregation of blood platelet
Rate increases, with the more significant difference (p of model control group<0.05, p<0.01, p<0.001；).The embodiment of the present invention 1 simultaneously
The middle and high dosage group of Chinese medicine composition group made from~3 is bright to erythrocyte aggregation rate, the inhibiting effect of maximum platelet aggregation rate
It is aobvious to be better than 1,2 group of comparative example, there is apparent advantage function (p<0.05, p<0.01) 3, be the results are shown in Table.
Table 3 to Rat Erythrocytes aggregation rate and maximum platelet aggregation rate influence (N=10)
Compared with blank control group△△p<0.01,△△△p<0.001；The * p compared with model control group<0.05, * * p<
0.01, * * * p<0.001；Compared with comparative example 1★p<0.05,★★p<0.01；Compared with comparative example 2#p<0.05,##p<0.01。
Influence to rat blood serum TG, TC, HDL-C, LDL-C：
Model control group rat blood serum TG, TC, LDL-C content significantly increases, and HDL-C contents are substantially reduced, with blank pair
Compare according to group and there were significant differences (p<0.001), atorvastatin calcium group, Chinese medicine composition made from the embodiment of the present invention 1~3
1,2 group of the basic, normal, high dosage group of group and comparative example can inhibit rat blood serum TG, TC, LDL-C content to increase in various degree, promote
Rat blood serum HDL-C discharges, there were significant differences compared with model control group (p<0.05、p<0.01).Chinese medicine group of the present invention simultaneously
The middle and high dosage group of object is closed compared with 1,2 group of comparative example, reduces TG, TC, LDL-C effect significantly, promotes HDL-C raisings effect
Significantly (p<0.05、p<0.01), show Chinese medicine composition made from the embodiment of the present invention 1~3 and 1,2 group of reduction blood fat of comparative example
The advantage of effect, the results are shown in Table 4.
Table 4 to rat blood serum TG, TC, HDL-C, LDL-C influence (N=10)
Compared with blank control group△△p<0.01,△△△p<0.001；The * p compared with model control group<0.05, * * p<
0.01, * * * p<0.001；Compared with comparative example 1★p<0.05,★★p<0.01；Compared with comparative example 2#p<0.05,##p<0.01。
Influence to rat blood serum SOD, MDA：
Model control group rat blood serum SOD vigor reduces, and MDA contents significantly increase, and relatively has with blank control group significantly
Difference (p<0.001), atorvastatin calcium group, the basic, normal, high dosage group of Chinese medicine composition group made from the embodiment of the present invention 1~3
And 1,2 group of comparative example can significantly increase rat blood serum SOD vigour changes, inhibit the release of MDA contents, compared with model control group
There were significant differences (p<0.05、p<0.01、p<0.001).Chinese medicine composition group made from the embodiment of the present invention 1~3 is middle and high simultaneously
Dosage group improves the effect of SOD vigor there were significant differences (p compared with 1,2 group of comparative example<0.05、p<0.01), middle and high dosage
Group inhibits MDA contents release actions there were significant differences (p<0.05), show that Chinese medicine composition of the present invention improves antioxidation, suppression
It makes the effect of its peroxidatic reaction of lipid to have a clear superiority, the results are shown in Table 5.
Table 5 to rat blood serum SOD, MDA influence (N=10)
Compared with blank control group△△p<0.01,△△△p<0.001；The * p compared with model control group<0.05, * * p<
0.01, * * * p<0.001；Compared with comparative example 1★p<0.05,★★p<0.01；Compared with comparative example 2#p<0.05,##p<0.01。
Embodiment 6
Tablet prepared by tablet and comparative example 1, comparative example 2 made of the Chinese medicine composition provided embodiment 1 to 3 into
The detection of row hardness, disintegration time limited, friability, active ingredient etc., testing result is as shown in 6~table of table 8：
The testing result of 6 production target of table
Note：Compared with comparative example 1,*Show with significant difference (P ＜ 0.05),**Show with pole significant difference (P ＜ 0.01)；
Compared with comparative example 2,#Show with significant difference (P ＜ 0.05),##Show with pole significant difference (P ＜ 0.01).
Volatile oil extracting：
Composition made from composition made from Example 1~3 and comparative example 1, comparative example 2, according to《Middle traditional Chinese medicines
Allusion quotation》Four essential oil extraction methods of version in 2015 continuously extract 8h, and with ether dissolution, volatile oil is obtained after anhydrous sodium sulfate drying.
Recovery rate is as shown in table 7.
Influence of the table 7 to volatile oil extracting rate
| Group | Volatile oil extracting rate (%) |
| The composition that embodiment 1 provides | 30*# |
| The composition that embodiment 2 provides | 35**## |
| The composition that embodiment 3 provides | 32*## |
| The composition that comparative example 1 provides | 23 |
| The composition that comparative example 2 provides | 20 |
Note：Compared with comparative example 1,*Show with significant difference (P ＜ 0.05),**Show with pole significant difference (P ＜ 0.01)；
Compared with comparative example 2,#Show with significant difference (P ＜ 0.05),##Show with pole significant difference (P ＜ 0.01).
Chromatographic condition：
Agilent 19091M-436 types quartz capillary column (0.25mm × 30m, 0.25 μm)；Carrier gas is height
Purity helium, volume flow 1mL/min, split ratio 50.2:1；280 DEG C of injector temperature；Temperature programming：60 DEG C (3min), 10
DEG C/min rises to 280 DEG C, keep 12min.1 μ L of sample size；Solvent delay 1.5min；Gasify 280 DEG C of room temperature；Multiplier voltage
1 952.9V。
Mass Spectrometry Conditions：
Electron bombardment (EI) ion source, ionization voltage 70eV；230 DEG C of ion source temperature；20~500amu of scanning range.
Under these experimental conditions, GC-MS analyses, inspection are carried out to the ingredient of the volatile oil in product made from embodiment 1
Go out 10 peaks.To each peak in total ion current figure after scanning of the mass spectrum mass spectrogram, through NIST08.L spectrograms library automatically retrieval and
Verification standard mass spectrogram with reference to related standard mass spectrum document, is identified 10 kinds of volatile oil component, is measured with areas of peak normalization method
Volatile oil each component percentage contents, the ingredient identified account for the 100% of complete oily total amount, the results are shown in Table 8.
The chemical composition and its relative amount of 8 volatile oil of table identification
Above-mentioned experiment, result of the test and the result of product made from embodiment 1 are carried out to product made from embodiment 2~3
Without significant difference (P ＞ 0.05).Show that offer technique provided by the invention is extracted using cryogenic high pressure difference, make active ingredient maximum
Degree extracts, and improves production efficiency.
The above is only the preferred embodiment of the present invention, it is noted that for the ordinary skill people of the art
For member, various improvements and modifications may be made without departing from the principle of the present invention, these improvements and modifications also should
It is considered as protection scope of the present invention.
Claims (10)
1. a kind of extraction process of drug, which is characterized in that include the following steps：
Bulk pharmaceutical chemicals include 500~600 parts by weight of hawthorn, 10~35 parts by weight of prepared fleece flower root, 10~35 parts by weight of cassia seed, lotus leaf
50~100 parts by weight；
Step 1：Bulk pharmaceutical chemicals is taken to be mixed after pre-processing with water；
Step 2：30~60min is extracted for the first time in 20~30Mpa, and 30~60min is extracted second then at 40~50Mpa；
Step 3：The extract that step 2 obtains is taken to collect filtrate through separation of solid and liquid.
2. extraction process according to claim 1, which is characterized in that the temperature of the first time extraction is 0~10 DEG C.
3. extraction process according to claim 1 or 2, which is characterized in that the temperature of second of extraction is 0~10
℃。
4. extraction process according to any one of claims 1 to 3, which is characterized in that separation of solid and liquid described in step 3 be from
The heart or filtering；The rotating speed of the centrifugation is 8000~12000rpm, and the time of the centrifugation is 10~30min.
5. extraction process according to any one of claims 1 to 4, which is characterized in that further include and the filtrate is taken to repeat to walk
Rapid 2, the step of step 3, the number of the repetition are at least 1 time.
6. extraction process according to claim 5, which is characterized in that further included after the step of repeating step 2, step 3
The step of merging filtrate, filtering；It is described to be filtered into micro-filtration；
The aperture for the film that the micro-filtration uses is 0.45~1.0 μm.
7. extraction process according to claim 6, which is characterized in that the micro-filtration is specially to take the filtrate after merging excessively micro-
Filter membrane adds water to make to be no less than 2 times of the volume of the filtrate after the merging through liquid measure, filters into dope the content of solid content
No less than 20% (w/w)；Microfiltration membranes are rinsed with water, cleaning solution is collected and is mixed with the dope.
8. the extraction process described according to claim 6 or 7, which is characterized in that the time of the filtering is no more than 6h, the mistake
The flow-reduction amplitude of filter is no less than 50%.
9. according to claim 6 to 8 any one of them extraction process, which is characterized in that the content of solid content in the filtering
For 10~20% (w/w), the relative density that 50~80 DEG C of whens measure is 1.05~1.20.
10. according to drug made from 1 to 9 any one of them extraction process.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810104820.3A CN108159146B (en) | 2018-02-02 | 2018-02-02 | Traditional Chinese medicine composition for reducing blood fat and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810104820.3A CN108159146B (en) | 2018-02-02 | 2018-02-02 | Traditional Chinese medicine composition for reducing blood fat and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108159146A true CN108159146A (en) | 2018-06-15 |
| CN108159146B CN108159146B (en) | 2020-12-22 |
Family
ID=62513046
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810104820.3A Active CN108159146B (en) | 2018-02-02 | 2018-02-02 | Traditional Chinese medicine composition for reducing blood fat and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108159146B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109350659A (en) * | 2018-12-10 | 2019-02-19 | 成都大学 | A kind of blood lipid-reducing blood sugar-decreasing composition and preparation method thereof, application |
-
2018
- 2018-02-02 CN CN201810104820.3A patent/CN108159146B/en active Active
Non-Patent Citations (3)
| Title |
|---|
| 中华人民共和国卫生部药典委员会编: "《中华人民共和国卫生部药品标准.中药成方制剂》", 31 December 1997 * |
| 刘超等: ""降脂宁颗粒质量标准的研究"", 《中国实验方剂学杂志》 * |
| 黄裕等: ""低温高压差提取抗敏中药复方的工艺研究"", 《中国药物经济学》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109350659A (en) * | 2018-12-10 | 2019-02-19 | 成都大学 | A kind of blood lipid-reducing blood sugar-decreasing composition and preparation method thereof, application |
| CN109350659B (en) * | 2018-12-10 | 2021-09-14 | 成都大学 | Lipid-lowering and blood-sugar-reducing composition, and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108159146B (en) | 2020-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103222988B (en) | A kind of American-cockroach-extract and its preparation method and application | |
| CN105395919B (en) | It is a kind of to contain black fungus extract, the composition with effect for reducing blood fat and preparation method thereof | |
| CN112961262A (en) | Passiflora edulis pericarp acidic polysaccharide, preparation method and application thereof | |
| CN102224924B (en) | Sea cucumber saponin-containing composition and its application in foods and drugs | |
| CN1558768A (en) | A pharmaceutical composition made from Chinese traditional medicine and preparation method thereof | |
| CN105796587B (en) | Caulis bambusae in taenian polysaccharide immunological regulation, it is antitumor in application | |
| CN108159146A (en) | A kind of Chinese medicine composition and preparation method for reducing blood lipid | |
| CN105012826B (en) | A kind of intelligence development leaf extract and preparation method thereof, application | |
| WO2020000828A1 (en) | Gracilaria lemaneiformis polysaccharide having significant hypolipidemic activity and preparation method therefor and use thereof | |
| CN108524668B (en) | Preparation method of Chinese wolfberry extract with repairing and treating effects on drug-induced liver injury | |
| CN102579530A (en) | Preparation method of aralia taibaiensis total saponin having diabetes mellitus resisting effect and medicament | |
| CN104031968A (en) | Walnut polypeptide and preparation method and application thereof | |
| CN105456277B (en) | Application of the ganodenic acid acid activity position in preparing blood fat reducing health products and drug | |
| CN106822071B (en) | Chinese medicinal effective component for treating coronary heart disease and hyperlipidemia, its preparation method and method for separating effective component from the same | |
| CN114588194A (en) | Biological component composition for improving blood viscosity and blood vessel embolism | |
| CN107854630B (en) | Rice bran extract and preparation method and application thereof | |
| CN113730466A (en) | Preparation method and application of blackberry extract | |
| CN105232802B (en) | Procyanidine composition with blood fat reducing effect and preparation method and application thereof | |
| CN105560310B (en) | Pharmaceutical application of Symplocos chinensis polysaccharide and composition thereof | |
| CN105193824A (en) | Tritepenoidic acid active site of ganoderma lucidum, method for preparing tritepenoidic acid active site and application thereof | |
| CN113713016B (en) | Application of seville orange flower in preparation of medicine for improving fatty liver | |
| CN1243443A (en) | Fresh rehmannia root extract for proliferation of bifidobactor and extraction method thereof | |
| CN104189101A (en) | Celandine seed fat-soluble part and hypolipidemic application thereof | |
| CN110507678B (en) | Application of water chestnut shell extract in preparing medicine for treating hyperlipemia | |
| CN107412607B (en) | Asparagus capsule and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: Xu Jian Inventor after: Bai Bing Inventor after: Xu Yun Inventor after: Xu Yanru Inventor after: Zhang Xiantao Inventor after: Li Zhibao Inventor after: Su Yanxia Inventor after: He Fan Inventor after: Chen Defeng Inventor before: Xu Jian Inventor before: Bai Bing Inventor before: Xu Yun Inventor before: Xu Yanru Inventor before: Zhang Xiantao Inventor before: Li Zhibao Inventor before: Xu Yanxia Inventor before: He Fan Inventor before: Chen Defeng |
|
| CB03 | Change of inventor or designer information | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220726 Address after: 130012 No. 1239, Shunda Road, high tech Development Zone, Changchun City, Jilin Province Patentee after: Xiuzheng Pharmaceutical Group Changchun High-new Pharmaceutical Co.,Ltd. Address before: 130012 4-6 / F, amendment building, 1369 Shunda Road, Changchun City, Jilin Province Patentee before: JILIN XIUZHENG PHARMACEUTICAL NEW MEDICINE DEVELOPMENT Co.,Ltd. |
|
| TR01 | Transfer of patent right |